Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Siramesine H Lundbeck.

C Heading1

  • 1moore11@globalnet.co.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|January 31, 2002
PubMed
Summary
This summary is machine-generated.

Siramesine, a sigma2 opioid agonist, is being developed for anxiety treatment. It has advanced to Phase II clinical trials, with Phase III trials anticipated soon.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of life in long-stay institutions in England: nurse and resident perceptions.

Journal of advanced nursing·1994
Same author

Anatomy and physiology of the urinary system.

Nursing·1987
Same author

Factors affecting bowel function.

Nursing·1987
Same author

Nursing assessment and management of constipation.

Nursing·1987
Same author

Nursing factors--diarrhoea.

Nursing·1987

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Development

Background:

  • Siramesine is a sigma2 opioid agonist.
  • It is under development by H Lundbeck.
  • It is being investigated as a potential treatment for anxiety.

Purpose of the Study:

  • To evaluate siramesine as a novel anxiolytic agent.
  • To advance siramesine through clinical development phases.
  • To identify potent backup compounds for anxiety treatment.

Main Methods:

  • Preclinical synthesis and testing of siramesine and related compounds.
  • Phase II clinical trials to assess efficacy and safety.
  • Planning and preparation for Phase III clinical trials.

Related Experiment Videos

Main Results:

  • Siramesine has successfully completed Phase II trials.
  • A strategic alliance with Forest Laboratories was established in 1998.
  • Development of backup compounds is ongoing.

Conclusions:

  • Siramesine shows promise as an anxiolytic medication.
  • Further clinical trials (Phase III) are planned.
  • Continued research aims to secure a robust pipeline of anxiety treatments.